• Earlier this month Oncoceutics confirmed that the United States Patent and Trademark Office (USPTO) has issued patent to the company with an expiration date of January 29, 2036. This newly issued patent covers the composition of matter for ONC213, its di-salt formulation, and its use in the treatment of cancer. In addition to the claims related to ONC213, the patent also contains claims for millions of structurally-related imipridones.

    Please find the full article here.

Photostream